Intellia to Present Lonvo-z Data at ACAAI Meeting
The company will detail clinical findings and commercial plans for its CRISPR gene editing candidate starting November 12, 2026.
Updated on Oct. 29, 2026 in Allergies
Live Poll
Would you prefer a single-dose genetic treatment over lifelong daily medication for a chronic condition?
Intellia Therapeutics will showcase seven presentations on its CRISPR gene editing candidate lonvo-z at the ACAAI 2026 Annual Scientific Meeting in Phoenix, Arizona, beginning November 12, 2026. This data release precedes a March 10, 2027, PDUFA target action date for the treatment of hereditary angioedema.
Why it matters
The upcoming presentations and investor webcast serve to highlight clinical progress and outline commercialization preparations for a potential new therapy. This update is critical for stakeholders tracking the regulatory timeline for the first-of-its-kind gene-editing application for this condition.
Intellia will share data across seven presentations, including follow-up results featuring a 50 mg dose for hereditary angioedema. The condition affects approximately one in 50,000 people, with further clinical outcomes pending the final FDA review process.
The players
Intellia Therapeutics
This biotechnology company is a leader in clinical-stage genome editing focused on developing therapies for severe diseases.
ACAAI
The American College of Allergy, Asthma & Immunology is a professional medical organization that hosts annual scientific gatherings.
FDA
The U.S. Food and Drug Administration is the federal regulatory body responsible for protecting public health through the oversight of medical products.
The details
The presentations cover the company's in vivo CRISPR gene editing candidate, lonvo-z, which is engineered to inactivate the KLKB1 gene. Intellia will also host an investor webcast to discuss key opinion leader insights and launch strategies for the potential treatment.
Timeline
September 2026: The FDA officially accepted the Biologics License Application for lonvo-z.
November 12, 2026: Intellia will host an investor webcast and begin participation at the ACAAI meeting.
November 13, 2026: Five poster presentations are scheduled to take place in Phoenix.
November 14, 2026: Two oral presentations regarding the gene editing candidate will be held.
March 10, 2027: The FDA has set this date as the PDUFA target action deadline.
Health Landscape
The development of lonvo-z relies on FDA Orphan Drug and RMAT designations, which are intended to fast-track innovation for rare conditions. This approach marks a significant evolution in medical science as it transitions CRISPR technology from laboratory research to potential clinical standard of care.
The potential approval of lonvo-z could introduce a new gene-editing treatment option for individuals living with hereditary angioedema. Patients and caregivers should monitor the March 2027 regulatory decision for updates on treatment availability and clinical implementation.
The takeaway
The upcoming scientific presentations provide a critical glimpse into the clinical and commercial roadmap for an advanced genetic therapy. Tracking the PDUFA timeline offers the best insight into when such innovative treatments might reach the market for patients.
Further reading
Find more updates on ongoing research in our Allergies section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Would you prefer a single-dose genetic treatment over lifelong daily medication for a chronic condition?
